Coya Therapeutics Enrolls 100th Participant In Phase 2/3 ALSTARS Trial Of COYA 302
Based on current screening and enrollment rates, topline data anticipated inearly Q2 2027Additional participants continue to roll over into the active extension arm of the trialCOYA 302 has received FDA Fast Track
Coya hit a milestone by enrolling 100 people in their big medicine trial. Watch for their results in early 2027 to see if the treatment works.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.